What type of study is this?

This is a Experimental Study study.

October 11, 2025BMC MicrobiologyOpen Access

Enhanced antibacterial activity of 3D-printed niosome-curcumin/ceftizoxime scaffolds against drug-resistant pathogens

View Full Paper

Ask AI

Bookmark

The Nio-CUR/CEF@SC system reduced MIC values against MRSA and CRKP to 0.25–1 µg/mL, showing strong antibacterial activity.
Encapsulation efficiency was high, with curcumin and ceftizoxime at 78% and 80%, respectively, ensuring effective delivery.
Cytotoxicity tests revealed over 90% viability of normal fibroblasts, indicating safety at effective doses.
The engineered nanocarrier shows promise for treating infections caused by drug-resistant pathogens in future research.

No takes yet. Share an insight, caveat, or question.

Experimental analysis shows 3D-printed niosome-curcumin/ceftizoxime scaffolds significantly reduce infection rates in drug-resistant pathogens.

Asalipisheh et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Experimental analysis shows 3D-printed niosome-curcumin/ceftizoxime scaffolds significantly reduce infection rates in drug-resistant pathogens.